MedTrace Logo

Study of WST09 in Prostate Cancer After Radiation: Repeat Procedure

NCT00305929 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2010-06-02

No results posted yet for this study

Summary

This is a multi-centre, phase II, open-label, 12-month clinical trial for patients previously treated with WST09 (Tookad) who have positive prostate biopsies for cancer.

The study aims at delivering a second WST09 treatment for the purpose of eradicating the localized prostate cancer.

Conditions

Interventions

DRUG

Treatment with Tookad VTP

DRUG

Treatment with Tookad VTP

Tookad 2 mg/kg

DRUG

Treatment with Tookad VTP

2 mg/kg

Sponsors & Collaborators

  • STEBA France

    lead INDUSTRY

Principal Investigators

  • John Trachtenberg, MD, FRCS(C) · University Health Network, Princess Margaret Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Completion
2007-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00305929 on ClinicalTrials.gov